Share Purchase by a Director

Redx Pharma plc

12 April 2024

 

REDX PHARMA PLC

("Redx" or the "Company")

Share Purchase by a Director

Alderley Park, UK, 12 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that it has been notified that Lisa Anson, Chief Executive Officer, has on Thursday 11 April 2024 acquired 399,000 Redx ordinary shares at a price of 7.5 pence per share.  Following this, Lisa Anson will hold 562,183 ordinary shares in the Company, representing 0.14 per cent. of the issued share capital.

Further information on the purchase is contained within the disclosure tables below.

For further information, please contact:
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications  [e-mail]		T: [phone]
SPARK Advisory Partners (Nominated Adviser)		T: [phone]
Matt Davis/ Adam Dawes
Panmure Gordon (UK) Limited (Broker)		T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting		T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.   

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

1.	Details of the person discharging managerial responsibilities (PDMR) / person closely associated
a)	Name	Lisa Anson
2.	Reason for the notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Redx Pharma plc
b)	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 1 pence each in Redx Pharma plc  ISIN for Redx Pharma plc Ordinary Shares:  GB00BSNB6S51
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Prices(a) and volume(s)	Purchase Price per Ordinary Share  Volume  7.5 pence  399,000 Ordinary Shares
d)	Aggregated information  - Aggregated volume  - Price	399,000 7.5p
e)	Date of the transaction	11 April 2024
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END